Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026

Arbutus Biopharma Corp

2023-FY EPS reported -$0.44 revenue$18,141,000

Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.
Cash, cash equivalents and investments $132.3M at Dec 31, 2023; 2024 net cash burn guided $63-67M.
Moderna LNP litigation claim construction held Feb 8, 2024; trial set for April 21, 2025.
Phase 2a imdusiran combo data readouts expected H1 2024; third imdusiran Phase 2a trial to start H1 2024.
AB-101 Phase 1a/1b preliminary data (healthy subjects) expected H1 2024.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Arbutus Biopharma Corp reported financial results for Fourth quarter and year ended December 31, 2023.

Period: Fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 29, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023 and certain other information.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001171843-24-001068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.